A method for performing an inhalation using a nebulizer includes filling a reservoir with a medication fluid or connecting a medication container to a designated connecting piece: connecting a nebulizer unit to a control unit and a mouthpiece, at least temporarily activating the nebulizer unit; atomizing the medication fluid into a fine particulate aerosol which is emitted into an aerosol chamber formed by the nebulizer unit and the mouthpiece during activation of the nebulizer unit; performing the inhalation, with a user enclosing the mouthpiece with the lips and during inhalation, drawing air from outside into the aerosol chamber, where the air mixes with the aerosol, and then passes further through the mouthpiece as an air stream and into the respiratory tract and, possibly into the user's lung; measuring a pressure within the aerosol chamber and/or a flow rate through the aerosol chamber or the mouthpiece using the control unit; activating the nebulizer unit with each breath on occurrence of at least one activation criterion detected using the control unit; and deactivating the nebulizer unit with fulfilment of at least one stop criterion, wherein from a degree of fulfilment of the at least one activation and/or stop criterion, a weighted average value is formed and the inhalation is started when the weighted average value exceeds a threshold value.

Devices, and methods for generating variable inhalable products (e.g., variable density, phase, and size products) are provided. Methods for treating or preventing a disorder in a subject using variable products generated by the devices are also provided herein. Additionally, inhalers and breathing systems comprising the devices are provided.

The present invention relates to parenteral formulations, and kits and methods suitable for the preparation of such parenteral formulations. The parenteral formulations comprise a freebase of a deuterium-substituted dimethyltryptamine optionally substituted at position 4 or 5 with acetoxy or methoxy. The parenteral formulations also comprise a biocompatible excipient. Such formulations are suitable for inhalation and have uses in the treatment of psychiatric or neurological disorders. They are metabolised more slowly than their protio analogues, allowing for a longer lasting therapeutic effect.

A system for treating and/or preventing a viral, bacterial and/or fungal infection in the oral cavity and/or along the respiratory tract, in particular the interior of the nose, throat, trachea and/or lungs, of a patient by reactive species generated by plasma as well as a plasma for such use is disclosed. The system comprises a plasma source generating reactive species in a gas, the plasma source being configured to be located outside a body of the patient, and a species directing member forming at least one duct for guiding at least a part of the reactive species generated by the plasma source into the oral cavity and/or the respiratory tract.

Provided is a smart inhaler and wearable smart mask configured to operate as an air ionizer and a controlled multi-liquid atomizer. The smart mask and smart inhaler use a mature technology to deliver various types of liquid solutions to different applications from health care, drug delivery, immunization to recreational and gaming uses. In addition, the smart mask contains multiple actuators to provide haptic feedback to the areas around the mask. The smart mask and inhaler have a direct communication path to a smart device or it can be a smart device by itself; its various environmental and gas sensors act as a feedback mechanism. The detection level of the organic and non-organic VOC gas emitted when exhaling can be communicated and stored for analysis purposes. The detected gas can be regenerated on the same smart mask or a different remote smart mask.

A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided. The dry powder inhaler can be provided with or without a unit dose cartridge for using with the inhaler. The inhaler and/or cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin, oxyntomodulin and glucagon-like peptide.

The present disclosure provides an aerosol delivery device and a liquid delivery and atomization assembly for use with an aerosol delivery device. In one implementation, the liquid delivery and atomization assembly comprises a liquid composition, an atomization assembly, and a liquid delivery component configured to transport at least a portion of the liquid composition to the atomization assembly. The liquid delivery component comprises at least one microchannel configured to deliver the portion of the liquid composition to the atomization assembly, and the microchannel includes a variable flow characteristic defined along at least a portion of the microchannel, the variable flow characteristic being configured to control the flow of the portion of liquid composition through the microchannel.

The presently disclosed subject matter is generally directed to a device that can be used for smoking a smokable product (such as tobacco). Particularly, the device includes a housing, cap, tube, and retainer. The housing and cap cooperate to provide a closed interior for burning an associated smokable product. The retainer functions to releasably attach the product (e.g., a cigarette) to one end of the tube. The tube passes through an opening in the cap such that a first portion of the tube is housed within the device interior and a second portion is positioned exterior to the device. The smokable product is burned within the interior of the device, and the user has access to the smoke produced by inhaling through the tube.

Some embodiments of an inhalation exposure system can deliver a gas, such as an aerosol, through a manifold to a set of exposure chambers in a controlled manner so as to achieve improved consistency for all of the test subjects.

Some embodiments of an inhalation exposure system can deliver a gas, such as an aerosol, to a set of exposure chambers in a controlled manner and can monitor one or more characteristics of the gas at a variety of aerosol delivery rates for output to a user interface. In some implementations, the improved user interface of the system may alert the user to a fitting range of aerosol delivery rates.